AgonOx Report issue

Foundation Phase 1 Phase 2

Organization Overview

First Clinical Trial
2014
NCT01689870
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AgonOx, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

anti-ox40 (1 trial)

ipilimumab (yervoy) (1 trial)

Drugs in Phase 1 Trials (2)

aldesleukin (Proleukin) (1 trial)

autologous tumor infiltrating lymphocytes (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 4